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Thyroid hormones are pleiotropic peptides with complex action on the human economy. The skeleton is a 
target tissue for thyroid hormone’s action, which is illustrated by the consequences of thyroid hormone excess 
and deficiency during development and during aging. Thyroid disorders are more frequently observed in older 
than in younger persons. Thyrotoxicosis is an established cause of secondary osteoporosis. Overt hyper-
thyroidism and iatrogenic hyperthyroidism due to over-replacement of thyroid hormone may result in fragility 
fractures. Endogenous or exogenous subclinical hyperthyroidism is associated with reduced bone density, 
especially in cortical bone in older women. Fragility fracture risk seems to be closely related to the degree of 
thyroid-stimulating hormone suppression and to other risk factors, including older age. Overt hyperthyroidism 
and endogenous subclinical hyperthyroidism in older persons should be treated to reduce the risk for fragility 
fractures, atrial fibrillation and related mortality risk. The risk for fragility fractures in older people, especially in 
postmenopausal women, taking suppressive doses of levothyroxine for thyroid cancer can be diminished by 
treatment with the minimal effective suppressive dose and in some cases, by adding an antiresorptive or bone 
forming therapy where indicated. Replacement therapy for overt hypothyroidism should be regularly adjusted 
to avoid TSH suppression and consequent increased risk of fragility fractures.
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IntroductIon
The relationship between thyroid function and bone has 
been empirically known for ages. Even if only in 1883 
the Nobel Laurate Theodor Kocher defined “cachexia 
strumipriva” as an illness characterized by decreased 
growth and height after thyroidectomy  1, the use of 
burnt sponge and seaweed in the treatment of goiter 
started as early as 1600 BC in China  2. The descrip-
tion of “cachexia strumipriva” finally led to the first 
substitution therapy with thyroid tissue preparations in 
1891 by George Murray 3; however, there is evidence 
that thyroid tissue was used as a treatment for goiter 
as early as the VII century AD in China. Also in 1891, 
Friedrich Von Recklinghausen reported for the first time 
a young woman who died from thyrotoxicosis with 
multiple fractures, and described the associated “worm 
eaten” appearance of long bones 4, identifying for the 
first time the relationship of thyroid hyperfunction and 
bone fragility fractures (FF) in the adult skeleton. The 
clinically overt hyperthyroid bone disease became less 
frequent after the introduction of effective treatment for 
hyperthyroidism with antithyroid drugs, surgery and ra-
dioiodine in the 1940’s 5. Nevertheless, bone loss and 
FF have been reported recently associated with overt 
and subclinical hyperthyroidism caused either by nodu-
lar toxic goiter or, more frequently, by over-replacement 
of thyroid hormone. Postmenopausal older women, 
who constitute a substantial portion of those on thyroid 
hormone, are remarkably prone to accelerated bone 
loss, while inadequately high doses of thyroid hormone 
may further increase their already high risk for FF.
Fragility fractures embody a major public health con-
cern expected to continue increasing due to aging of 
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the population  6. The substantial burden associated 
with FF is caused by derived morbidity and disability, 
which also entail high social costs. Fragility fractures 
significantly compromise patients’ quality of life and 
financially overwhelm health care systems. Over half of 
patients never regain their previous functional capacity 
after a hip fracture and near one quarter move to long-
term care facilities 7. One year mortality rates after hip 
fracture are estimated as 14-36% 6 8. The direct costs 
of FF in the US were estimated in 19  billion dollars 
(2005) with an expected 50% increase by 2025 9. The 
cost of osteoporosis in the EU in 2010 was estimated at 
€ 37 billion, while in Italy it was estimated at near € 7 bil-
lion 6. Major risk factors for osteoporosis include age, 
reduced physical activity, previous FF, a family history of 
osteoporotic fracture, the use of corticosteroids, and al-
cohol abuse 10. Altered thyroid function, more frequently 
observed in older than in younger persons, is also a risk 
factor for FF, which can be particularly unfavorable in 
older people. Its detection and treatment is crucial es-
pecially because it is a potentially reversible cause of FF. 
The present review briefly explores the relationship of 
thyroid function alterations and fragility fracture risk in 
older age. 
thyroId FunctIon, bone, and agIng 
The direct action of thyroid hormone on the skeleton 
is certainly evidenced by the delayed epiphyseal de-
velopment and poor growth of infants with congenital 
hypothyroidism or with thyroid hormone resistance 11. 
Skeletal tissue expresses all isoforms of thyroid hor-
mone receptor (TR), which possibly interact with other 
nuclear receptors (i.e., vitamin D and retinoids recep-
tors) 12 13. Circulating osteocalcin levels and mRNA are 
associated with thyroid status, with osteocalcin mRNA 
expression in bone being stimulated by the active thy-
roid hormone 3,5,3’ -L- triiodothyronine (T3) in specific 
locations, such as the hip, which is particular predis-
posed to osteoporosis in hyperthyroid patients 13. Stud-
ies in mutant mice have established the concept that T3 
has anabolic actions during growth and catabolic ef-
fects on adult bone. Thyroid-stimulating hormone (TSH) 
receptor is expressed in many extrathyroidal tissues 
including bone and it has been suggested that TSH 
may have direct actions on bone turnover  14, and on 
immunomodulatory responses in the bone marrow  15 
and bone cells 16. Actions of T3 and TSH in osteocytes 
have not been investigated; in chondrocytes, T3 inhibits 
proliferation and stimulates chondrocyte differentiation, 
while TSH may inhibit proliferation and matrix synthesis; 
T3 stimulates bone resorption but it is currently uncer-
tain whether T3 acts directly in osteoclasts or indirectly 
via its effects on the osteoblasts. Most studies indicate 
that T3 stimulates osteoblast differentiation and bone 
formation, while there is inconsistent observations sug-
gesting that TSH may stimulate, inhibit or have no effect 
on osteoblast differentiation and function  17. Thyroid 
hormone metabolism in the osteoblast is a fine tune 
mechanism for the maintenance of intracellular T3 con-
centrations, through the expression of deiodinases D2 
(activator) and D3 (inactivator), which activities vary in 
the euthyroid, hypothyroid or hyperthyroid state 18.
In organ culture, T3 directly stimulates bone resorp-
tion 19, most probably through nuclear TR 20. Studies in 
experimental animals lacking TR-alpha or TR-beta sug-
gest that bone resorption is mediated by TR-alpha 21. 
Thyroid hormone may alter calcium metabolism by a 
direct action on osteoclasts, or via its action on osteo-
blasts, which consecutively stimulate osteoclastic bone 
resorption  22. Another mediator of thyroid hormone-
stimulated bone loss is the elevated concentration of 
interleukin-6 in hyperthyroidism 23. Table I summarizes 
the effects of thyroid hormone deficiency or excess on 
bone turnover, growth, bone mass and fracture risk.
thyroId hyperFunctIon In older age
Thyroid disorders are more common in older than in 
younger populations, predominantly in women, and 
they are frequently disregarded because their signs and 
symptoms often mimic age-associated modifications or 
disease of other organs. For example, hypothyroidism 
may induce or worsen cognitive and physical decline, 
constipation, cold intolerance, body weight gain, and 
anemia or lipid disorders, all frequently observed in 
euthyroid older people. Likewise, thyroid hyperfunction 
may manifest as arrhythmia and congestive heart failure, 
which may be interpreted as the expression of cardiac 
disease, very frequent in old age. Weight loss associ-
ated with hyperthyroidism may be taken as part of the 
normal aging process, undernutrition or neoplasia, also 
frequent in old age. Thyroid hyperfunction may as well 
be asymptomatic or “apathetic” presented merely with 
subtle signs, again frequently misinterpreted as normal 
age-associated changes, or as reduced thyroid func-
tion. Indeed, older people may have similar manifesta-
tions that correspond to increased or decreased thyroid 
function, such as, mental confusion, depression, falling 
and FF, walking disturbances, urinary incontinence from 
immobility, congestive heart failure, constipation or diar-
rhea. These signs also correspond to other disorders 
commonly observed in older people 24. Overt or, more 
frequently, subclinical hyperthyroidism may increase 
significantly the risk for FF, which may be ascribed to 
other risk factors present in older people. 
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Hyperthyroidism is found in 0.5% to 3% of all older pa-
tients 25-27. These numbers are higher when considering 
older people living in long-term care facilities, even if 
studies in this setting are few and most include a limited 
number of patients 28. It is noteworthy that in two stud-
ies  29  30 unnecessary therapy with levothyroxine was 
disclosed in 15.4% 29 and 50% 30 of nursing home resi-
dents, with important implications for health and quality 
of life, perhaps increasing the risk for FF and atrial fibril-
lation in this already high risk population. Hence, the 
detection of subclinical thyroid dysfunction, and overt 
disease, is essential to correctly identify the subjects at 
true risk. It is also possible that subtle thyroid alterations 
in younger people may evolve to overt clinical manifes-
tation during aging. For example, non-toxic goiter start-
ing as a diffuse thyroid enlargement during early life may 
acquire nodularity and autonomous function with aging 
and may progress, although not frequently, to toxic 
nodular goiter. Before becoming clinically apparent, 
toxic goiter may show only slight laboratory modifica-
tions conforming subclinical states of thyroid dysfunc-
tion. Comorbidity and polypharmacy may further mask 
or mimic the presentation of thyroid disease. The lack of 
evident clinical manifestations of thyroid dysfunction in 
the older adults requests an attentive clinical evaluation 
and a high index of suspicion to identify their presence, 
with the appropriate confirmation by means of reliable 
laboratory testing. Nevertheless, thyroid tests may also 
have minimal changes with age and caution in the inter-
pretation of such changes is warranted 24.
Overt hyperthyrOidism
This condition is certainly associated with acceler-
ated bone turnover, decreased bone mineral density 
(BMD) (reported as 10-28%), and increased fracture 
rate. BMD reduction may or may not be reversible with 
hyperthyroidism therapy. Overt hyperthyroidism is as-
sociated with hypercalciuria and, infrequently, hyper-
calcemia. A histomorphometric study showed a small 
reduction in trabecular bone volume (-2.7%) with a 
marked increased cortical bone resorption (+40%) and 
porosity (+32%), with no changes in osteoid volume 31. 
Osteoclastic resorption is strikingly activated overcom-
ing osteoblastic action with a 50% reduction in the 
cycle duration and about 10% loss of mineralized bone 
in each cycle  32. Conversely, there is a 17% increase 
in mineralized bone for each cycle in hypothyroidism. 
Some studies have shown normalization of BMD after 
treatment of hyperthyroidism  33-36. However, there are 
other studies reporting only partial recovery of BMD af-
ter treatment 37-41. A more recent cross-sectional study 
showed that women with a past history of hyperthy-
roidism had a higher prevalence of BMD in the range 
of osteoporosis  42. The heterogeneity of these results 
is probably due to different duration of hyperthyroidism 
before treatment, various time intervals of follow up, 
and diverse techniques and sites of BMD. Even with 
the variability of BMD, a past history of hyperthyroidism 
increases the risk for FF (43-45), and may help to explain 
the higher later mortality in these patients  46. Interest-
ingly, a study showed that hyperthyroid patients treated 
with radioiodine had an increased risk of forearm and 
vertebral fractures compared to patients also treated 
with methimazole, in whom there was no increase in 
fractures  47. This may reflect a tendency of overtreat-
ment in patients with levothyroxine replacement therapy 
after radioiodine ablation. Likewise, a prospective study 
of women aged over 65  years followed for 3.7  years 
showed that those with TSH lower or equal to 0.1 mU/L 
at baseline had an increased risk for hip (RR  =  3.6) 
and vertebral (RR = 4.5) fractures  48. Increased bone 
resorption in patients with hyperthyroidism may lead to 
hypercalcemia (although not frequently), reduction of 
parathyroid hormone secretion, and hypercalciuria with 
a consequent negative calcium balance 49, and reduced 
activation of 25-OH-vitamin  D  50. Osteoprotegerin  51, 
fibroblast growth factor-23 52, and urinary excretion of 
bone collagen-derived pyridinium cross-links  53 have 
been found increased in overt hyperthyroidism.
Therefore, patients with overt hyperthyroidism should 
receive adequate amounts of dietary or supplemental 
calcium and vitamin D.
subclinical hyperthyrOidism
The finding of TSH levels below 0.45 mU/L in the pres-
ence of thyroid hormones in the normal or high border-
line range is indicative of subclinical hyperthyroidism, 
which is more frequent than overt disease  54  55. The 
most common causes of subclinical hyperthyroidism 
are an initial Graves’ disease, initial nodular toxic goiter, 
excessive TSH suppressive therapy with levothyroxine 
for benign thyroid nodular disease or for differentiated 
thyroid cancer, or hormone over-replacement in pa-
tients with hypothyroidism. However, other causes of a 
low TSH, such as non-thyroidal illness, fasting, and the 
use of drugs (i.e., glucocorticoids) should be excluded 
before making the diagnosis. Subclinical hyperthyroid-
ism in older people may be associated with relevant 
signs and symptoms of excessive thyroid hormone ac-
tion, and in particular, with an increased risk of FF, atrial 
fibrillation, and increased mortality risk  24 54 55. Indeed, 
it is becoming increasingly apparent that subclinical 
hyperthyroidism may decrease BMD and accelerate 
the development of osteoporosis and FF, particularly in 
postmenopausal women with a preexisting predisposi-
tion 56 57; hence, patients with low TSH levels should be 
carefully evaluated (Fig. 1).
A study investigating nursing home residents with low 
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TSH and normal total 3,5,3’,5’-L-tetraiodothyronine 
(thyroxine, T4) levels showed that only 3 out of 40 pa-
tients with subclinical hyperthyroidism became overt 
hyperthyroid. However, 17.5% of patients with sub-
clinical hyperthyroidism died during the first 4 months 
of follow-up compared to 7.5% in a control group  58. 
In a meta-analysis of studies in men with subclini-
cal hyperthyroidism, excess all-cause mortality was 
related to the years since diagnosis and to advanced 
age  59. There are variable results regarding BMD and 
subclinical hyperthyroidism, but most suggest an as-
sociated low BMD 56 60. Interestingly, in healthy euthy-
roid postmenopausal women from the Osteoporosis 
and Ultrasound Study (OPUS) those in the highest 
quintile of normal free T4 (FT4) at baseline had lower 
BMD after 6 years of follow-up compared with women 
in the lowest quintile of FT4 61. A recent meta-analysis 
of 13 prospective cohort studies from the US, Europe, 
Australia, and Japan (n  =  70,298), compared par-
ticipants with euthyroidism (TSH 0.45-4.49  mIU/L) to 
those with endogenous subclinical hypothyroidism and 
hyperthyroidism in the incidence of FF after a median 
follow-up of 12.1 years. Considering all participants and 
after adjusting for age and sex, there was a significant 
increased risk of hip (HR  =  1.36, 95% CI:1.13-1.64), 
and any (HR  =  1.28, 95% CI:1.06-1.53) fracture for 
participants with subclinical hyperthyroidism vs. euthy-
roidism. The increased risk was even higher for those 
with TSH < 0.10 mIU/L (HR = 1.61, 95% CI:1.21-2.15 
for hip fracture; HR = 1.98, 95% CI:1.41-2.78 for any 
fracture; HR  =  3.57, 95% CI:1.88-6.78 for vertebral 
fracture). For endogenous subclinical hyperthyroidism 
(excluding those on thyroid medications) there was an 
increased risk of hip (HR  =  1.52, 95% CI:1.19-1.93), 
any (HR  =  1.42, 95% CI 1.16-1.74), and vertebral 
(HR = 1.74, 95% CI 1.01-2.99) fractures 62. No associa-
tion was found between subclinical hypothyroidism and 
fracture risk. Besides the effects of thyroid hormone on 
bone turnover and BMD, which may help explain the 
increased FF incidence, it is pertinent to considered 
also an increased risk of falls through effects on muscle 
strength and coordination. 
In view of the fact that subclinical hyperthyroidism and 
its related clinical manifestations are reversible, may 
cause in some cases significant morbidity and mor-
tality, and may be prevented by timely treatment, it is 
important to consider the possible benefit of treatment 
on an individual basis. Most authors agree regarding 
considering treatment of older patients with subclinical 
hyperthyroidism and a clearly suppressed TSH level 
(< 0.1 mUI/L) and follow up for patients with TSH levels 
between 0.1 and 0.4  mUI/L  54  55. Further studies are 
needed to determine whether treating subclinical hy-
perthyroidism can prevent fractures.
exogenous thyroId hormone therapy
Subclinical hyperthyroidism due to levothyroxine thera-
py is not uncommon, with potential increased bone re-
sorption, reduced BMD, and increases FF risk. The risk 
of FF seems to be linked to the degree of TSH suppres-
sion and to other factors (i.e., advanced age), which fur-
ther increase that risk. There are variable results regard-
ing BMD changes associated with over-replacement 
with thyroid hormone therapy. However, most studies 
have demonstrated that even moderate suppressive 
doses of T4 can cause bone loss in postmenopausal 
women. Two meta-analyses of studies exploring BMD 
in patients with subclinical hyperthyroidism due to T4 
therapy are available 63 64. A significantly reduced BMD 
was found only in postmenopausal women, similar 
to previous findings in cross-sectional studies. The 
meta-analysis by Uzzan et al. found a reduced BMD 
Table I. Summary of effects of thyroid hormone deficiency or excess on bone turnover, growth, bone mass and fracture risk.
Hypothyroidism Hyperthyroidism
bone turnover Reduced Increased
bone remodeling cycle Prolonged Reduced
young skeleton
•	 growth velocity Reduced Increased
•	 bone mineralization Reduced Increased
•	 bone age Reduced Increased
•	 Final height Reduced, disproportioned Reduced, proportioned
adult skeleton
•	 bone mass Increased Reduced
•	 FF risk Increased (by stiffness) Increased (by fragility)
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in postmenopausal and also in premenopausal women 
with levothyroxine replacement therapy 64. 
Regarding FF risk, the results are not uniform with 
some 48 65 but not all  66 studies showing an increased 
fracture risk in patients with subclinical hyperthyroid-
ism due to exogenous thyroid hormone therapy. The 
inconsistent results may be due to diverse populations 
studied and different degrees of TSH suppression. For 
example, in a study involving 17,648 patients on levo-
thyroxine therapy those with undetectable TSH had a 
twofold increased risk of FF when compared to those 
with TSH between 0.04 and 0.4 mU/L 65. 
A study involving 1,180 patients on levothyroxine ther-
apy showed that near 60% had a TSH < 0.05 mU/L) 66. 
In this study, even if women aged over 65 years with 
suppressed TSH values had 2.5% FF vs 0.9% of those 
with normal TSH values, the difference did not reach 
statistical significance. In another study of 686 women 
aged over 65 years, those with TSH ≤ 0.1 mU/L had a 
4-fold increased risk of FF vs. those with normal TSH 48.
thyroId nodule and levothyroxIne 
therapy
Most of thyroid nodules (~  95%), which occur with 
increasing frequency in older age, are benign. None-
theless, clinical evaluation has been considered for all 
thyroid nodules given the potential risk of evolving into 
thyroid malignancy (Fig. 2). The prevalence of palpable 
thyroid nodules is near 5% in women and 1% in men 
living in iodine-sufficient areas. Conversely, the preva-
lence increases to 19-68% for thyroid nodules detected 
by high-resolution ultrasound, with higher frequency in 
women and older people  67  68. It has been estimated 
that approximately 7-15% of thyroid nodules may 
evolve into thyroid malignancy depending on sex, age, 
history of radiation exposure, and family history among 
others  69  70. The risk of malignancy is similar for soli-
tary nodules and multinodular goiters; urgent referral to 
secondary care is necessary only if the nodule is grow-
ing rapidly (over few weeks) or associated with stridor, 
Figure 1. Algorithm for the diagnosis of altered serum TSH concentrations. TSH: thyroid stimulating hormone; FT4: free thyroxine; 
FT3: free triiodothyronine; rT3: reverse triiodothyronine; AF: atrial fibrillation; NTI: non-thyroidal illness; ATAb: anti-thyroid antibodies.
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hoarseness, or cervical lymphadenopathy 71. Generally, 
goiter size increases with aging and thyroid nodular-
ity develops, with the largest goiters observed in the 
oldest age groups living in iodine deficient areas. The 
prevalence of diffuse and nodular goiter in young adults 
participating in an iodine deficient area survey (Pesco-
pagano study) was 30% in young adults and increased 
up to 75% in the age group 55-65 years, with nodular 
goiter accounting for about one third of the total  72. 
Multinodular goiter, usually longstanding, is frequently 
seen in old age, and thyroid hormone suppressive 
therapy not only is not indicated but may contribute 
to exogenous hyperthyroidism with heart and bone 
adverse effects. A nodule(s) in multinodular goiter may 
become autonomous with aging and progress to overt 
thyrotoxicosis, while large goiters may cause obstruc-
tive symptoms. The physical examination of women 
with goiter may be complicated by hyperkyphosis and 
changes in posture associated with osteoporosis; if the 
thyroid gland can be palpated in an older woman, it 
is probably enlarged. Calcification of large goiters may 
be associated to dyspnea, dysphagia, or dysphonia 
and can be misdiagnosed as cancer metastases to 
lymphoid nodes, hence, Fine-needle aspiration biopsy 
(FNA) is recommended to determine the nature of calci-
fied lesions 73. 
According to the American Thyroid Association (ATA) 
guidelines, thyroid ultrasound should not be performed 
as a screening test; however, patients with a palpable 
thyroid nodule should undergo ultrasound examination. 
Management depends mainly on the results of FNA but 
should also take into consideration the clinical and ul-
trasound features. Solid hypoechoic nodules and nod-
ules with suspicious sonographic appearance (irregular 
margins, microcalcifications, taller than wide shape, rim 
calcifications, or evidence of extrathyroidal extension) 
should undergo FNA when ≥ 1 cm (as determined by 
largest dimension). Nodules with sonographic appear-
ance suggesting a low risk for thyroid cancer can be 
undergo FNA when larger (≥ 1.5 to 2 cm). Spongiform 
nodules ≥ 2 cm could also be evaluated by FNA, al-
though observation without FNA is an alternative op-
tion 74. When a goiter is asymptomatic, follow-up is the 
choice, while treatment is necessary in case of toxic 
Figure 2. Algorithm for the diagnosis and management of thyroid nodule. FNA: fine-needle aspiration; MNG: multinodular goiter; 
TSH: thyroid-stimulating hormone; US: ultrasound; ATAb: anti-thyroid anti-bodies.
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goiter or compressive symptoms. 131-I is the first choice 
treatment for thyroid autonomy and hyperthyroidism, 
whereas surgery is advised for large non-toxic goiters 
causing significant compressive symptoms. 131-I ther-
apy has been proposed in order to reduce thyroid vol-
ume in non-toxic goiters, with satisfactory results, even 
in the presence of structural and functional heterogene-
ity, and large variability in 131-I dose. Pretreatment with 
recombinant TSH (rhTSH) may increase the efficacy 
of 131-I therapy 75. FNA is the most accurate method in 
the evaluation of a thyroid nodule, helping to determine 
which patients should be referred for surgery. Its ac-
curacy is improved by high-resolution ultrasound guid-
ance, which can also add useful information 71. 
Thyroid cancer is mostly (> 90%) differentiated, which 
includes papillary and follicular cancer 76. Thyroid cancer 
in old age is also generally well-differentiated, but their 
course is frequently less predictable than in younger 
patients. Lymphoma of the thyroid and undifferentiated 
cancers, even if rare, occur with increasing frequency in 
old age. The incidence of thyroid cancer in the US has 
tripled from 1975 to 2009 with most of new cases being 
papillary thyroid cancer. The proportion of tumors lower 
or equal to 1 cm was 25% in the period 1988-1989 vs 
+ 39% in 2008–2009 77. This may be attributable to the 
rising use of neck ultrasonography and other imaging 
techniques, which may help to improve the long-term 
health outcomes for patients with thyroid neoplasms. 
However, a comprehensive and rational evaluation of 
thyroid nodule is needed to avoid excessively alarming 
the patients and improper overuse of imaging exams. 
A recent prospective, multicenter, observational study 
included 992 consecutive patients with 1 to 4 asympto-
matic ultrasound and cytologically benign thyroid nod-
ules. Participants were recruited from eight hospital-
based thyroid-disease referral centers in Italy between 
2006 and 2008. Available results correspond to the first 
5 years of follow-up. The primary end point was nodule 
growth assessed with yearly thyroid ultrasound. Signifi-
cant size changes were considered as ≥ 20% modifica-
tions in at least two nodule diameters, with a minimum 
increase of 2  mm. Baseline factors associated with 
nodule growth were identified. Secondary end points 
were the sonographic detection of new nodules and the 
diagnosis of thyroid cancer during follow-up. From the 
1,567 original nodules, only 174 (11.1%) increased in 
size. Nodule growth was associated with the presence 
of multiple nodules (OR, 2.2 for 2 nodules; OR, 3.2 for 3 
nodules; and OR, 8.9 for 4 nodules), and male sex (OR, 
1.7). Age equal or higher than 60 years was associated 
with a lower risk of nodule growth compared to nodules 
in persons younger than 45  years (OR, 0.5). Thyroid 
cancer was diagnosed in 5 original nodules (0.3%), and 
only two of them had grown. New nodules developed 
in 93 patients (9.3%), with detection of only one cancer. 
Therefore, in this large prospective study, the majority 
of ultrasound or cytologically benign thyroid nodules 
exhibited no significant size increase during 5 years of 
follow-up and thyroid cancer was rare  78. These find-
ings strongly supported consideration of revision of 
current guideline recommendations for follow-up of 
asymptomatic thyroid nodules. In the latest ATA guide-
lines, recommendation 25 explicitly states that “routine 
TSH suppression therapy for benign thyroid nodules 
in iodine sufﬁcient populations is not recommended. 
Though modest responses to therapy can be detected, 
the potential harm outweighs beneﬁt for most patients 
(Strong recommendation, High-quality evidence)” 74.
Ultrasound monitoring of benign thyroid nodules is 
initially recommended at 12  months, then at increas-
ing intervals (e.g., 2 to 5 years, with the shorter interval 
for large nodules or nodules with suspicious ultrasound 
features and the longer interval for smaller nodules with 
benign ultrasonographic features). Repeated FNA might 
be performed only when there is substantial growth 
(> 50% change in volume or 20% increase in at least 
two nodule dimensions), new suspicious ultrasound 
features, or new symptoms attributed to a nodule. 
tsh suppressIon In thyroId cancer
Another important issue regards the cardiac and skel-
etal effects of long-term TSH suppression used to 
reduce thyroid cancer recurrence. According to recent 
guidelines from the ATA, it is necessary to consider age, 
the presence of preexisting cardiovascular and skeletal 
risk factor, and the aggressiveness of thyroid cancer to 
decide the TSH target, and to better balance the benefit 
vs. the potential adverse effects of long-term TSH sup-
pression. In addition, adequate intake of calcium and 
vitamin  D to prevent osteoporosis should be encour-
aged 79. Many authors in the past have recommended 
that patients with thyroid cancer should maintain very 
low serum TSH concentrations (less than 0.01 mU/L). 
However, in one report, serum thyroglobulin con-
centrations did not fall further when serum TSH was 
suppressed below 0.1  mU/L  80. This emphasizes the 
importance of tailoring the levothyroxine dose to the 
extent of the disease and the likelihood of recurrence.
The ATA initial risk stratification system estimates the risk 
of persistent/recurrent disease. This system is designed 
to stratify patients as having either low (papillary thyroid 
cancer confined to thyroid), intermediate (regional me-
tastases, worrisome histologies, extrathyroidal exten-
sion, or vascular invasion), or high (gross extrathyroidal 
extension, distant metastases, or postoperative serum 
thyroglobulin suggestive of distant metastases) risk of 
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recurrence, primarily based upon clinicopathologic find-
ings 74.
After initial thyroidectomy, whether or not radioiodine 
therapy is administered, thyroid hormone (levothyrox-
ine) therapy is required in most patients to prevent hy-
pothyroidism and to minimize potential TSH stimulation 
of tumor growth, as follows:
•	 for	 patients	with	 low-risk	 disease	 treated	with	 thy-
roidectomy who have detectable serum thyroglobu-
lin levels (with or without remnant ablation), the se-
rum TSH initially can be maintained between 0.1 and 
0.5 mU/L. For similar patients who have undetect-
able serum thyroglobin levels (with or without rem-
nant ablation) or who were treated with lobectomy, 
TSH can be maintained in the mid to lower half of the 
reference range (0.5 to 2.0 mU/L). In the later setting, 
thyroid hormone treatment may be unnecessary if a 
patient can maintain their TSH in this range;
•	 for	 patients	 with	 intermediate-risk	 disease,	 the	 se-
rum TSH initially can be maintained between 0.1 and 
0.5 mU/L;
•	 for	 patients	with	 high-risk	 disease,	 the	 serum	TSH	
initially should be less than 0.1 mU/L. 
TSH concentrations are measured annually and 
6-8 weeks after any dose adjustments of levothyroxine. 
Although TSH should be maintained < 0.1 mU/L in pa-
tients with a structurally incomplete response, patients 
with a better response to therapy can have their TSH 
goal modified, for example:
•	 for	 patients	 initially	 with	 high-risk	 disease	 but	 who	
have an excellent or indeterminate clinical response 
to therapy, a TSH goal of 0.1 to 0.5 mU/L for up to 
5 years is acceptable, after which time the degree of 
suppression can be further relaxed (with continued 
surveillance for recurrence);
•	 for	 patients	 initially	 with	 low-risk	 disease	 and	 who	
have an excellent clinical response to therapy, a TSH 
goal of 0.5 to 2 mU/L is acceptable;
•	 for	 patients	 with	 a	 biochemically	 incomplete	 re-
sponse, the serum TSH should be maintained be-
tween 0.1 and 0.5 mU/L 74.
conclusIons
The skeleton is a target tissue for thyroid hormone’s ac-
tion, certainly verified by the consequences of thyroid 
hormone excess and deficiency during development 
and during aging. Old age may be associated with a 
number of thyroid function alterations. However, it is 
not simple to discern whether and to what extent these 
changes are expression of the aging process per se or 
of an age-associated thyroidal and/or nonthyroidal ill-
ness and polypharmacy. There is often significant delay 
and difficulty in the diagnosis of thyroid disorders in old 
age because clinical presentation is paucisymptomatic 
and attributed to normal aging, and because atypical 
presentations are not uncommon. Routine screening 
of asymptomatic, healthy adults is not recommended; 
however, physicians should maintain a high index of 
suspicion for testing thyroid function in subjects at risk. 
Thyroid diseases in older patients differ from those ob-
served in younger patients in their prevalence, which is 
higher especially among women, and clinical expres-
sion, while their treatment often deserves special at-
tention because of the increased risk of complications 
(i.e. cardiac arrhythmia, cognitive decline, bone loss). 
Subclinical abnormalities of thyroid function are more 
prevalent than overt disease in older populations. 
Subclinical hyperthyroidism appears to be a significant 
risk factor for cardiac arrhythmia, especially atrial fibril-
lation, and FF in old age. The risk is particularly high 
among those with TSH levels below 0.10 mIU/L. The 
benefits of treatment of subclinical disease are not 
completely elucidated. Treatment of thyroid disease 
deserves especial attention in old-old patients because 
of the increased risk of complications and the lack of 
evidence-based data in this population.
Even if most of thyroid nodules in older persons are be-
nign, clinical evaluation should be considered to timely 
identified thyroid malignancy. FNA remains the corner-
stone of thyroid cancer diagnosis, which accuracy may 
be improved by high-resolution ultrasound evaluation. 
Thyroid hormones may lead to accelerated bone turno-
ver and over-replacement of levothyroxine can result in 
increased FF risk. The majority of cytologically benign 
thyroid nodules do not have significant size increase and 
in these nodules thyroid cancer was rare after a 5-year 
follow up. The risk for osteoporosis in postmenopausal 
women taking suppressive doses of levothyroxine for 
thyroid cancer can be minimized by treatment with the 
minimal effective suppressive dose and eventual insti-
tution of antiresorptive or bone forming therapy where 
indicated, emphasizing the importance of tailoring the 
levothyroxine dose to the extent of the disease and the 
likelihood of recurrence.
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